|Mr. Kare Schultz||Pres, CEO & Director||5.6M||N/A||1961|
|Mr. Eliyahu Sharon Kalif||Exec. VP & CFO||655.76k||N/A||1973|
|Dr. Hafrun Fridriksdottir||Exec. VP of Global R&D||2.48M||N/A||1962|
|Mr. Brendan P. O'Grady||Exec. VP of North America Commercial||1.56M||N/A||1967|
|Mr. Gianfranco Nazzi||Exec. VP of International Markets Commercial||2.15M||N/A||1970|
|Mr. Eric DrapÃ©||Exec. VP of Global Operations||N/A||N/A||1962|
|Mr. Andrew J. Weil CPA||Chief Accounting Officer||N/A||N/A||1967|
|Mr. Kevin C. Mannix||Sr. VP of Investor Relations||N/A||N/A||N/A|
|Mr. David M. Stark||Exec. VP & Chief Legal Officer||N/A||N/A||1969|
|Ms. Lori Queisser||Sr. VP & Global Compliance Officer||N/A||N/A||N/A|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Teva Pharmaceutical Industries Limited’s ISS governance QualityScore as of 3 December 2020 is 3. The pillar scores are Audit: 3; Board: 1; Shareholder rights: 6; Compensation: 4.